BACKGROUND/AIMS: To investigate the degree of cyclooxygenase-2 (COX-2) protein expression in chronic hepatitis and cirrhosis. METHODS: COX-2 protein expression was evaluated in 43 cases of chronic hepatitis and 24 cases of cirrhosis using immunohistochemical techniques. The COX-2 immunohistochemical staining score was assessed using the scoring systems of Pazirandeh et al and Qiu et al. and each scoring system was based on a sum of the parameters of staining intensity and distribution. RESULTS: The mean COX-2 expression scores in chronic hepatitis and cirrhosis were 2.5 ± 1.3 vs. 3.3 ± 1.1 (p = 0.008), and 3.2 ± 2.0 vs. 4.5 ± 1.7 (p = 0.006), respectively, based on the Pazirandeh et al. and Qiu et al. scoring systems. The percentage samples of high COX-2 expression score (4 to 5) in chronic hepatitis and cirrhosis were 16.3% vs. 45.8% (p = 0.022), and 23.3% vs. 50% (p = 0.021), respectively, based on the two scoring systems. The mean COX-2 expression scores based on the severity of hepatic fibrosis scored using Ishak's modified staging system (fibrosis score 0 to 3 vs. 4 to 6) were 2.4 ± 1.3 vs. 3.2 ± 1.1 (p = 0.009), and 3.1 ± 2.0 vs. 4.3 ± 1.8 (p = 0.009), respectively, based on the two scoring systems. CONCLUSIONS: COX-2 expression was significantly higher in liver cirrhosis group than in chronic hepatitis. COX-2 expression scores according to Ishak's staging was significantly higher in the advanced fibrosis group. COX-2 may play a role in the progression of hepatic fibrosis.
BACKGROUND/AIMS: To investigate the degree of cyclooxygenase-2 (COX-2) protein expression in chronic hepatitis and cirrhosis. METHODS:COX-2 protein expression was evaluated in 43 cases of chronic hepatitis and 24 cases of cirrhosis using immunohistochemical techniques. The COX-2 immunohistochemical staining score was assessed using the scoring systems of Pazirandeh et al and Qiu et al. and each scoring system was based on a sum of the parameters of staining intensity and distribution. RESULTS: The mean COX-2 expression scores in chronic hepatitis and cirrhosis were 2.5 ± 1.3 vs. 3.3 ± 1.1 (p = 0.008), and 3.2 ± 2.0 vs. 4.5 ± 1.7 (p = 0.006), respectively, based on the Pazirandeh et al. and Qiu et al. scoring systems. The percentage samples of high COX-2 expression score (4 to 5) in chronic hepatitis and cirrhosis were 16.3% vs. 45.8% (p = 0.022), and 23.3% vs. 50% (p = 0.021), respectively, based on the two scoring systems. The mean COX-2 expression scores based on the severity of hepatic fibrosis scored using Ishak's modified staging system (fibrosis score 0 to 3 vs. 4 to 6) were 2.4 ± 1.3 vs. 3.2 ± 1.1 (p = 0.009), and 3.1 ± 2.0 vs. 4.3 ± 1.8 (p = 0.009), respectively, based on the two scoring systems. CONCLUSIONS:COX-2 expression was significantly higher in liver cirrhosis group than in chronic hepatitis. COX-2 expression scores according to Ishak's staging was significantly higher in the advanced fibrosis group. COX-2 may play a role in the progression of hepatic fibrosis.
Authors: T P Reilly; J N Brady; M R Marchick; M Bourdi; J W George; M F Radonovich; C A Pise-Masison; L R Pohl Journal: Chem Res Toxicol Date: 2001-12 Impact factor: 3.739
Authors: A S L Cheng; H L Y Chan; N W Y Leung; C T Liew; K F To; P B S Lai; J J Y Sung Journal: Aliment Pharmacol Ther Date: 2002-02 Impact factor: 8.171
Authors: Jun Yu; Chung W Wu; Eagle S H Chu; Alex Y Hui; Alfred S L Cheng; Minnie Y Y Go; Arthur K K Ching; Yiu L Chui; Henry L Y Chan; Joseph J Y Sung Journal: Biochem Biophys Res Commun Date: 2008-05-27 Impact factor: 3.575
Authors: Nicholas J Skill; Campbell M Elliott; Brian Ceballos; Romil Saxena; Robert Pepin; Lisa Bettcher; Matthew Ellensberg; Daniel Raftery; Mary A Malucio; Burcin Ekser; Richard S Mangus; Chandrashekhar A Kubal Journal: Ann Transplant Date: 2019-06-11 Impact factor: 1.530
Authors: B Alipoor; S Nikouei; F Rezaeinejad; S-N Malakooti-Dehkordi; Z Sabati; H Ghasemi Journal: J Endocrinol Invest Date: 2021-04-01 Impact factor: 4.256
Authors: Soon Ha Kwon; Soung Won Jeong; Jae Young Jang; Ji Eun Lee; Sae Hwan Lee; Sang Gyune Kim; Young Seok Kim; Young Deok Cho; Hong Soo Kim; Boo Sung Kim; So-Young Jin Journal: Clin Mol Hepatol Date: 2012-09-25